HeadSense

Company Overview

Snapshot

Founded in April 2011, HeadSense operates with 11–50 employees. The company has secured funding across two rounds from three investors, including Pontifax.

Business overview

HeadSense Medical develops noninvasive intracranial pressure (ICP) monitors designed to assist in treating patients with severe traumatic brain injury (TBI), stroke, and brain tumors. Its core product, the HS-1000, utilizes a disposable headset that emits an acoustic signal through the ear and skull, analyzed by a proprietary algorithm to provide ICP levels. The device serves the healthcare industry, specifically hospitals and healthcare providers, operating within the Health Tech & Life Sciences sector, with a focus on medical devices, patient remote monitoring, and digital healthcare.

Strategic signal

In July 2013, HeadSense secured an A Round of funding from investors including Pontifax and GE Ventures. This investment validated the potential of HeadSense's noninvasive intracranial pressure monitoring technology, signaling investor confidence in its application for conditions like traumatic brain injury, stroke, and brain tumors.

Company Intelligence Q&A

What is HeadSense's primary product?

HeadSense's primary product is the HS-1000, a noninvasive intracranial pressure (ICP) monitor designed for continuous monitoring in patients with severe traumatic brain injury, stroke, and brain tumors.

When was HeadSense founded?

HeadSense was founded in April 2011.

Which investors participated in HeadSense's A Round funding?

In July 2013, HeadSense received an A Round of funding from investors including Pontifax and GE Ventures.

What type of technology does HeadSense utilize for monitoring?

HeadSense's technology involves a disposable headset that transmits an acoustic signal through the ear and skull, which is then analyzed by a proprietary signal-processing algorithm to determine ICP levels.